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Background: Most “vulnerable plaques” progress from stable phenotype (pathologic intimal thickening: PIT) to thick-cap (ThC) fibroatheromas 
(FA) and then to thin-cap fibroatheromas (TCFA) prior to rupture. While hypercholesterolemia (Hchol) is associated with greater atherosclerotic 
plaque burden assessed by grayscale intravascular ultrasound (IVUS), it is unknown whether Hchol is a risk factor for vulnerable plaques.
Methods: In PROSPECT, a 3-vessel imaging study that assessed the natural history of culprit and non-culprit lesions in 697 pts with acute coronary 
syndrome, the proximal untreated 6-8cm of all 3 coronary arteries were studied using virtual histology (VH) IVUS that classified tissue as fibrous, 
fibrofatty, dense calcium, or necrotic core and lesions as PIT, fibrotic, fibrocalcific, ThCFA, or TCFA.
Results: Hchol status and analyzable VH-IVUS were available in 632 pts of whom 279 pts (44.1%) had medically treated Hchol. The length of artery 
imaged in pts with vs. without Hchol was 177.4±66.6 vs. 172.1±60.9mm, p=0.5. The number of lesions (plaque burden >40% in 3 consecutive 
frames) in pts with vs. without Hchol was 4.9±1.9 vs. 5.0±1.9, p=0.3. Pts with medically treated Hchol had more necrotic core, more FAs, and fewer 
stable lesions (i.e., PIT) than those without Hchol (Table).
Conclusions: Patients with medically treated Hchol have higher necrotic core volumes and more FAs than those without hypercholesterolemia 
supporting Hchol as a risk factor for precursors of vulnerable plaques. 
Hypercholesterolemia
279 pts with 1185 lesions
NoHypercholesterolemia
353 pts with 1486 lesions
p-value
Average VH-IVUS lesion plaque volume (%)
Necrotic Core 13.7±8.6 12.3±8.5 <0.0001
Dense Calcium 7.1±6.7 6.0±6.5 <0.0001
Fibrous 58.8±9.5 59.8±9.5 0.004
Fibrofatty 20.4±11.7 21.8±12.1 0.002
VH-IVUS lesion phenotype (%)
Any FA (TCFA or ThCFA) 63.5% 57.2% 0.0009
- TCFA 22.4% 22.1% 0.82
- ThCFA 41.1% 35.1% 0.002
PIT 33.2% 38.9% 0.003
Fibrotic 1.9% 3.0% 0.09
Fibrocalcific 1.3% 0.9% 0.42
